Indaptus Secures $24M via Private Placement at Nasdaq Minimum Price
INDP has more than doubled off its 52-week low of $0.92 on elevated volume (8.2× avg).
Summary
Indaptus Therapeutics agreed to sell 20.34 million shares for ~$24 million in a private placement priced at the Nasdaq Minimum Price plus $0.015, with proceeds earmarked for working capital and early-stage research into a sleep-related neurotechnology device.
Key Events · Financing and Capital Events · INDP
-
$24M Private Placement
Indaptus agreed to sell 20,338,974 shares for approximately $24.0 million gross proceeds at the Nasdaq Minimum Price plus $0.015 per share.
-
~15% Dilution
With 133,242,324 shares outstanding before the deal, the new shares represent roughly 15% additional dilution to existing holders.
-
Strategic Pivot to Neurotechnology
Proceeds may fund early-stage research and preclinical evaluation of a neurotechnology/neural-network-based device for sleep-related conditions, with a view toward a future FDA submission.
-
Going Concern Backdrop
The company has no active clinical trials and a going concern warning; this capital extends runway but at a meaningful cost to existing shareholders.
Analysis · INDP · Life Sciences
On September 8, 2026, Indaptus entered into a stock purchase agreement to sell 20,338,974 shares for approximately $24.0 million in gross proceeds. The per-share price is the Nasdaq Minimum Price plus $0.015, which is the lower of the prior day's close or the five-day average close. With 133,242,324 shares outstanding before the deal, the new shares represent roughly 15% additional dilution. The company has no active clinical trials and a going concern warning, so this capital extends runway but comes at a meaningful cost to existing holders. The use of proceeds includes a pivot toward a neurotechnology device for sleep-related conditions, a notable strategic shift for a company that recently discontinued its Decoy20 program.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INDP was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $277.1M. The 52-week trading range was $0.92 to $8.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.